<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OKT3- muromonab-cd3 injection, solution </strong><br>Centocor Ortho Biotech Products, L.P.<br></p></div>
<h1>ORTHOCLONE OKT<span class="Sup">®</span>3 STERILE SOLUTION<br> (muromonab-CD3)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Intravenous Use Only</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First">Only physicians experienced in immunosuppressive therapy and management of solid organ transplant patients should use ORTHOCLONE OKT3 (muromonab-CD3). Patients treated with ORTHOCLONE OKT3 must be managed in a facility equipped and staffed for cardiopulmonary resuscitation and where the patient can be closely monitored for an appropriate period based on his or her health status.</p>
<p>Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur following administration of any dose or course of ORTHOCLONE OKT3. In addition, serious, occasionally life-threatening or lethal, systemic, cardiovascular, and central nervous system reactions have been reported following administration of ORTHOCLONE OKT3. These have included: <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, especially in patients with volume overload; <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, cardiac or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, cerebral herniation, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Fluid status should be carefully monitored prior to and during ORTHOCLONE OKT3 administration. Pretreatment with methylprednisolone is recommended to minimize symptoms of Cytokine Release Syndrome. (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>, <a href="#WARNINGS_CNS">Central Nervous System Events</a>, <a href="#WARNINGS_Anaphylactic"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a>; <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ORTHOCLONE OKT3 (muromonab-CD3) Sterile Solution is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant. It is for intravenous use only. The antibody is a biochemically purified IgG<span class="Sub">2a</span> immunoglobulin with a heavy chain of approximately 50,000 daltons and a light chain of approximately 25,000 daltons. It is directed to a glycoprotein with a molecular weight of 20,000 in the human T cell surface which is essential for T cell functions. Because it is a monoclonal antibody preparation, ORTHOCLONE OKT3 Sterile Solution is a homogeneous, reproducible antibody product with consistent, measurable reactivity to human T cells.</p>
<p>Each 5 mL ampule of ORTHOCLONE OKT3 Sterile Solution contains 5 mg (1 mg/mL) of muromonab-CD3 in a clear colorless solution which may contain a few fine translucent protein particles. Each ampule contains a buffered solution (pH 7.0 ± 0.5) of monobasic sodium phosphate (2.25 mg), dibasic sodium phosphate (9.0 mg), sodium chloride (43 mg), and polysorbate 80 (1.0 mg) in water for injection.</p>
<p>The proper name, muromonab-CD3, is derived from the descriptive term murine monoclonal antibody. The CD3 designation identifies the specificity of the antibody as the Cell Differentiation (CD) cluster 3 defined by the First International Workshop on Human Leukocyte Differentiation Antigens.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">ORTHOCLONE OKT3 reverses <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>, probably by blocking the function of T cells which play a major role in <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span>. OTHOCLONE OKT3 reacts with and blocks the function of a 20,000 dalton molecule (CD3) in the membrane of human T cells that has been associated <span class="Italics">in vitro</span> with the antigen recognition structure of T cells and is essential for signal transduction. In <span class="Italics">in vitro</span> cytolytic assays, ORTHOCLONE OKT3 blocks both the generation and function of effector cells. Binding of ORTHOCLONE OKT3 to T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> results in early activation of T cells, which leads to cytokine release, followed by blocking T cell functions. After termination of ORTHOCLONE OKT3 therapy, T cell function usually returns to normal within one week.</p>
<p><span class="Italics">In vivo</span>, ORTHOCLONE OKT3 reacts with most peripheral blood T cells and T cells in body tissues, but has not been found to react with other hematopoietic elements or other tissues of the body.</p>
<p>A rapid and concomitant decrease in the number of circulating CD3 positive cells, including those that are CD2, CD4, or CD8 positive has been observed in patients studied within minutes after the administration of ORTHOCLONE OKT3. This decrease in the number of CD3 positive T cells results from the specific interaction between ORTHOCLONE OKT3 and the CD3 antigen on the surface of all T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. T cell activation results in the release of numerous cytokines/lymphokines, which are felt to be responsible for many of the acute clinical manifestations seen following ORTHOCLONE OKT3 administration. (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>, <a href="#WARNINGS_CNS">Central Nervous System Events</a>.)</p>
<p>While CD3 positive cells are not detectable between days two and seven, increasing numbers of circulating CD2, CD4, and CD8 positive cells have been observed. The presence of these CD2, CD4, and CD8 positive cells has not been shown to affect reversal of rejection. After termination of ORTHOCLONE OKT3 therapy, CD3 positive cells reappear rapidly and reach pre-treatment levels within a week. In some patients however, increasing numbers of CD3 positive cells have been observed prior to termination of ORTHOCLONE OKT3 therapy. This reappearance of CD3 positive cells has been attributed to the development of neutralizing antibodies to ORTHOCLONE OKT3, which in turn block its ability to bind to the CD3 antigen on T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. (See: <a href="#PRECAUTIONS_Sensitization">PRECAUTIONS: Sensitization</a>.)</p>
<p>Pediatric patients are known to have higher CD3 lymphocyte counts than adults. Pediatric patients receiving ORTHOCLONE OKT<span class="Sup">®</span>3 therapy often require progressively higher doses of ORTHOCLONE OKT3 to achieve depletion of CD3 positive cells (&lt;25 cells/mm<span class="Sup">3</span>) and ensure therapeutic ORTHOCLONE OKT3 serum concentrations (&gt;800 ng/mL). (See: <a href="#DA">DOSAGE AND ADMINISTRATION</a>; <a href="#PRECAUTIONS_Laboratory">PRECAUTIONS: Laboratory Tests</a>.)</p>
<p>Serum levels of ORTHOCLONE OKT3 are measurable using an enzyme-linked immunosorbent assay (ELISA). During the initial clinical trials in renal allograft rejection, in patients treated with 5 mg per day for 14 days, mean serum trough levels of the drug rose over the first three days and then averaged 900 ng/mL on days 3 to 14. Serum concentrations measured daily during treatment with ORTHOCLONE OKT3 in renal, hepatic, and cardiac allograft recipients revealed that pediatric patients less than 10 years of age have higher levels than patients 10–50 years of age. Subsequent clinical experience has demonstrated that serum levels greater than or equal to 800 ng/mL of ORTHOCLONE OKT3 blocks the function of cytotoxic T cells <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>. Reduced T cell clearance or low plasma ORTHOCLONE OKT3 levels provide a basis for adjusting ORTHOCLONE OKT3 dosage or for discontinuing therapy. (See: <a href="#WARNINGS_Anaphylactic">WARNINGS: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a>; <a href="#PRECAUTIONS_Laboratory">PRECAUTIONS: Laboratory Tests</a>; <a href="#AE_Hypersensitivity">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a>; <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Following administration of ORTHOCLONE OKT3 <span class="Italics">in vivo</span>, leukocytes have been observed in cerebrospinal and peritoneal fluids. The mechanism for this effect is not completely understood, but probably is related to cytokines altering membrane permeability, rather than an active inflammatory process. (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>, <a href="#WARNINGS_CNS">Central Nervous System Events</a>.)</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Acute Renal Rejection</h2>
<p class="First">In a controlled randomized clinical trial, ORTHOCLONE OKT3 was compared with conventional high-dose steroid therapy in reversing acute renal allograft rejection. In this trial, 122 evaluable patients undergoing acute rejection of cadaveric renal transplants were treated either with ORTHOCLONE OKT3 daily for a mean of 14 days, with concomitant lowering of the dosage of azathioprine and maintenance steroids (62 patients), or with conventional high-dose steroids (60 patients). ORTHOCLONE OKT3 reversed 94% of the rejections compared to a 75% reversal rate obtained with conventional high-dose steroid treatment (p=0.006). The one year Kaplan-Meier (actuarial) estimates of graft survival rates for these patients who had acute rejection were 62% and 45% for ORTHOCLONE OKT3 and steroid-treated patients, respectively (p=0.04). At two years the rates were 56% and 42%, respectively (p=0.06).</p>
<p>One- and two-year patient survivals were not significantly different between the two groups, being 85% and 75% for ORTHOCLONE OKT3 treated patients and 90% and 85% for steroid-treated patients.</p>
<p>In additional open clinical trials, the observed rate of reversal of acute renal allograft rejection was 92% (n=126) for ORTHOCLONE OKT3 therapy. ORTHOCLONE OKT3 was also effective in reversing acute renal allograft rejections in 65% (n=225) of cases where steroids and lymphocyte immune globulin preparations were contraindicated or were not successful.</p>
<p>The effectiveness of ORTHOCLONE OKT3 for prophylaxis of renal allograft rejection has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Acute Cardiac or Hepatic Allograft Rejection</h2>
<p class="First">ORTHOCLONE OKT3 was studied for use in reversing acute cardiac and hepatic allograft rejection in patients who are unresponsive to high-doses of steroids. The rate of reversal in acute cardiac allograft rejection was 90% (n = 61) and was 83% for hepatic allograft rejection (n = 124) in patients unresponsive to treatment with steroids.</p>
<p>Controlled randomized trials have not been conducted to evaluate the effectiveness of ORTHOCLONE OKT3 compared to conventional therapy as first line treatment for acute cardiac and hepatic allograft rejection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ORTHOCLONE OKT3 is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span> in renal transplant patients.</p>
<p>ORTHOCLONE OKT3 is indicated for the treatment of steroid-resistant <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span> in cardiac and hepatic transplant patients.</p>
<p>The dosage of other immunosuppressive agents used in conjunction with ORTHOCLONE OKT3 should be reduced to the lowest level compatible with an effective therapeutic response. (See: <a href="#WARNINGS">WARNINGS</a> and <a href="#AE_Infections">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a>, <a href="#AE_Neoplasia">Neoplasia</a>; <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ORTHOCLONE OKT3 should not be given to patients who:</p>
<ul class="Disc">
<li> are hypersensitive to this or any other product of murine origin;</li>
<li> have anti-mouse antibody titers ≥1:1000;</li>
<li> are in (uncompensated) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or in <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>, as evidenced by chest X-ray or a greater than 3 percent <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> within the week prior to planned ORTHOCLONE OKT3 administration;</li>
<li> have <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>;</li>
<li> have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or are predisposed to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>;</li>
<li> are determined or suspected to be pregnant, or who are breast-feeding. (See: <a href="#PRECAUTIONS_Pregnancy">PRECAUTIONS: Pregnancy</a>, <a href="#PRECAUTIONS_Nursing">Nursing Mothers</a>.)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><a href="#BOX">SEE BOXED WARNING</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGS_Cytokine"></a><a name="section-7.1"></a><p></p>
<h2>Cytokine Release Syndrome</h2>
<p class="First">Most patients develop an acute clinical syndrome [i.e., Cytokine Release Syndrome (CRS)] that has been attributed to the release of cytokines by activated <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or monocytes and is temporally associated with the administration of the first few doses of ORTHOCLONE OKT<span class="Sup">®</span>3 (particularly, the first two to three doses). This clinical syndrome has ranged from a more frequently reported mild, self-limited, "flu-like" illness to a less frequently reported severe, life-threatening <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like reaction, which may include serious cardiovascular and central nervous system manifestations. The syndrome typically begins approximately 30 to 60 minutes after administration of a dose of ORTHOCLONE OKT3 (but may occur later) and may persist for several hours. The frequency and severity of this symptom complex is usually greatest with the first dose. With each successive dose of ORTHOCLONE OKT3, both the frequency and severity of the Cytokine Release Syndrome tends to diminish. Increasing the amount of ORTHOCLONE OKT3 or resuming treatment after a hiatus may result in a reappearance of the CRS.</p>
<p>Common clinical manifestations of CRS may include: high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (often spiking, up to 107°F), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, muscle/<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Less frequently reported adverse experiences include: minor dermatologic reactions (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, etc.) and a spectrum of often serious, occasionally fatal, cardiorespiratory and central nervous system adverse experiences.</p>
<p>Cardiorespiratory findings may include: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>/failure/distress, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, angina/<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>/tightness, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (including ventricular), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> including profound <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> (cardiogenic and non-cardiogenic), <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. (See: <a href="#BOX">BOXED WARNING</a>; <a href="#PRECAUTIONS">PRECAUTIONS</a>; <a href="#AE">ADVERSE EVENTS</a>.)</p>
<p>In the initial studies of renal allograft rejection, potentially fatal, severe <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> occurred in 5% of the initial 107 patients. <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid overload</span> was present before treatment in all of these cases. It occurred in none of the subsequent 311 patients treated with first-dose volume/weight restrictions. In subsequent trials and in post-marketing experience, severe <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> has occurred in patients who appeared to be euvolemic. The pathogenesis of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> may involve all or some of the following: volume overload; increased pulmonary vascular permeability; and/or reduced left ventricular compliance/contractility. During the first 1 to 3 days of ORTHOCLONE OKT3 therapy, some patients have experienced an acute and transient decline in the glomerular filtration rate (GFR) and diminished urine output with a resulting increase in the level of serum creatinine. Massive release of cytokines appears to lead to reversible renal functional impairment and/or delayed renal allograft function. Similarly, transient elevations in hepatic transaminases have been reported following administration of the first few doses of ORTHOCLONE OKT3.</p>
<p>Patients at risk for more serious complications of CRS may include those with the following conditions: <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>; recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or symptomatic <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>; <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of any etiology; <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> of any etiology; any form of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>; intravascular volume overload or depletion of any etiology (e.g., excessive dialysis, recent intensive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, blood loss, etc.); cerebrovascular disease; patients with advanced symptomatic vascular disease or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>; a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>. Efforts should be made to correct or stabilize background conditions prior to the initiation of therapy. (See: <a href="#PRECAUTIONS">PRECAUTIONS</a>.)</p>
<p>Prior to administration of ORTHOCLONE OKT3, the patient's volume (fluid) status and a chest X-ray should be assessed to rule out volume overload, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>, or uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients should not weigh &gt;3% above their minimum weight during the week prior to injection.</p>
<p>The Cytokine Release Syndrome is associated with increased serum levels of cytokines (e.g., TNF-α, IL-2, IL-6, IFN-γ) that peak between 1 and 4 hours following administration of ORTHOCLONE OKT3. The serum levels of cytokines and the manifestations of CRS may be reduced by pretreatment with 8 mg/kg of methylprednisolone (i.e., high-dose steroids), given 1 to 4 hours prior to administration of the first dose of ORTHOCLONE OKT3, and by closely following recommendations for dosage and treatment duration. (See: <a href="#DA">DOSAGE AND ADMINISTRATION</a>.) It is not known if corticosteroid pretreatment decreases organ damage and sequelae associated with CRS. For example, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and cerebral herniation have occurred despite pretreatment with currently recommended doses and schedules of methylprednisolone.</p>
<p>If any of the more serious presentations of the Cytokine Release Syndrome occur, intensive treatment including oxygen, intravenous fluids, corticosteroids, pressor amines, antihistamines, intubation, etc., may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGS_CNS"></a><a name="section-7.2"></a><p></p>
<h2>Central Nervous System Events</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have been reported, even following the first dose, during therapy with ORTHOCLONE OKT<span class="Sup">®</span>3. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, some accompanied by <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or cardiorespiratory arrest, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have occurred independently or in conjunction with any of the neurologic syndromes described below.</p>
<p>A few cases of fatal cerebral herniations subsequent to <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> have been reported. All patients, particularly pediatric patients, must be carefully evaluated for <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> before the initiation of ORTHOCLONE OKT3 therapy. Close monitoring for <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> must be performed during the first twenty - four (24) hours following each of the first few doses of ORTHOCLONE OKT3 injection.</p>
<p>Patients should be closely monitored for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and manifestations of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, including: impaired cognition, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, altered mental status, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, auditory/<span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (<span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>), <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, combativeness, etc.), diffuse hypotonus, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, involuntary movements, major motor <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>/<span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>/<span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and diffuse <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Approximately one-third of patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> may have had coexisting <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome.</p>
<p>Signs and symptoms of the <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome described in association with the use of ORTHOCLONE OKT3 have included: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningismus</span> (<span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span>), and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>. Diagnosis is confirmed by cerebrospinal fluid (CSF) analysis demonstrating <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> with <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span>, elevated protein and normal or decreased glucose, with negative viral, bacterial, and fungal cultures. The possibility of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be evaluated in any immunosuppressed transplant patient with clinical findings suggesting <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. Approximately one-third of the patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> had coexisting signs and symptoms of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Most patients with the <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome had a benign course and recovered without any permanent sequelae during therapy or subsequent to its completion or discontinuation. However, because <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> is a frequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> encountered in pediatric allograft recipients, and the <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> associated with transplantation increases the risk of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>, pediatric patients with signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningeal irritation</span> while receiving ORTHOCLONE OKT3 should have lumbar punctures performed to rule out an infectious etiology. (See: <a href="#PRECAUTIONS_Pediatric">PRECAUTIONS: Pediatric Use</a>.)</p>
<p>Signs or symptoms of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, with or without <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, typically have been reversible. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and less severe forms of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> resolved in most patients despite continued treatment with ORTHOCLONE OKT3. However, some events resulted in permanent neurologic impairment.</p>
<p>The following additional central nervous system events have each been reported: irreversible <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, impaired vision, quadri-or <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/plegia, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span> (<span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>/plegia), <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, transient ischemic attack, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span> of the VI cranial nerve, hearing decrease, and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>.</p>
<p>Patients who may be at greater risk for CNS adverse experiences include those: with known or suspected CNS disorders (e.g., history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, etc.); with cerebrovascular disease (small or large vessel); with conditions having associated neurologic problems (e.g., head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbance</span>, etc.); with underlying vascular diseases; or who are receiving a medication concomitantly that may, by itself, affect the central nervous system. (See: <a href="#WARNINGS">WARNINGS</a>, <a href="#PRECAUTIONS">PRECAUTIONS</a> and <a href="#AE_Cytokine">ADVERSE EVENTS: Cytokine Release Syndrome</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGS_Anaphylactic"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h2>
<p class="First">Serious and occasionally fatal, immediate (usually within 10 minutes) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients treated with ORTHOCLONE OKT3. <span class="Bold">Manifestations of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may appear similar to manifestations of the Cytokine Release Syndrome (described above). It may be impossible to determine the mechanism responsible for any systemic reaction(s).</span> Reactions attributed to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported less frequently than those attributed to cytokine release. Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may be characterized by: <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, cardiorespiratory arrest, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including laryngeal, pharyngeal, or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>), airway obstruction, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Bold">Serious allergic events, including anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, have been reported in patients re-exposed to ORTHOCLONE OKT3 subsequent to their initial course of therapy. Pretreatment with antihistamines and/or steroids may not reliably prevent <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> in this setting. Possible allergic hazards of retreatment should be weighed against expected therapeutic benefits and alternatives. If a patient is retreated with ORTHOCLONE OKT3, it is particularly important that epinephrine and other emergency life-support equipment should be immediately available.</span></p>
<p><span class="Bold">If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> is suspected, discontinue the drug immediately; do not resume therapy or re-expose the patient to ORTHOCLONE OKT3</span>. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require emergency treatment with 0.3 mL to 0.5 mL aqueous epinephrine (1:1000 dilution) subcutaneously and other resuscitative measures including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated. (See: <a href="#PRECAUTIONS_Cytokine">PRECAUTIONS: Cytokine Release Syndrome vs. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a>; <a href="#AE_Hypersensitivity">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGS_Consequences"></a><a name="section-7.4"></a><p></p>
<h2>Consequences of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and neoplasias have been reported in association with all immunosuppressive therapies, including those regimens containing ORTHOCLONE OKT<span class="Sup">®</span>3.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGS_Infections"></a><a name="section-7.4.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h3>
<p class="First">ORTHOCLONE OKT3 is usually added to immunosuppressive therapeutic regimens, thereby augmenting the degree of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. This increase in the total amount of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may alter the spectrum of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> observed and increase the risk, the severity, and the morbidity of infectious complications. During the first month post-transplant, patients are at greatest risk for the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: (1) those present prior to transplant, perhaps exacerbated by post-transplant <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>; (2) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> conveyed by the donor organ; and (3) the usual post-operative urinary tract, intravenous line related, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>, or pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacterial pathogens. (See: <a href="#AE_Infections">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a>.)</p>
<p>Approximately one to six months post-transplant, patients are at risk for <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> [e.g., cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), etc.] which produce serious systemic disease and which also increase the overall state of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>.</p>
<p>Reactivation (1 to 4 months post-transplant) of EBV and CMV has been reported. When administration of an anti-lymphocyte antibody, including ORTHOCLONE OKT3, is followed by an immunosuppressive regimen including cyclosporine, there is an increased risk of reactivating CMV and impaired ability to limit its proliferation, resulting in symptomatic and disseminated disease. EBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, either primary or reactivated, may play an important role in the development of post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. (See: <a href="#WARNINGS">WARNINGS</a> and <a href="#AE_Neoplasia">ADVERSE EVENTS: Neoplasia</a>.)</p>
<p>In the pediatric transplant population, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> often include pathogens uncommon in adults, such as <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV), adenovirus, and respiratory syncytial virus (RSV). A large proportion of pediatric patients have not been infected with the herpes viruses prior to transplantation and, therefore, are susceptible to developing primary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> from the grafted organ and/or blood products.</p>
<p>Geriatric patients may have a reduced capability to overcome <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during intense <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. There is no information on the use of OKT3 in geriatric patients. In an age-stratification analysis, no overall difference in the safety of OKT3 was noted between older (51 to 64 years) and younger (≤30 years) patients. Caution should be used when prescribing immunosuppressive agents to elderly patients.</p>
<p>Anti-infective prophylaxis may reduce the morbidity associated with certain potential pathogens and should be considered for pediatric and other high-risk patients. Judicious use of immunosuppressive drugs, including type, dosage, and duration, may limit the risk and seriousness of some <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. It is also possible to reduce the risk of serious CMV or EBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by avoiding transplantation of a CMV-seropositive (donor) and/or EBV-seropositive (donor) organ into a seronegative patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGS_Neoplasia"></a><a name="section-7.4.2"></a><p></p>
<h3>Neoplasia</h3>
<p class="First">As a result of depressed cell-mediated immunity from immunosuppressive agents, organ transplant patients have an increased risk of developing malignancies. This risk is evidenced almost exclusively by the occurrence of <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>, squamous cell carcinomas of the skin and lip, and <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>. In immunosuppressed patients, T cell cytotoxicity is impaired allowing for transformation and proliferation of EBV-infected B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Transformed B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> are thought to initiate oncogenesis, which ultimately culminates in the development of most post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. Patients, especially pediatric patients, with primary EBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be at a higher risk for the development of EBV-associated <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. Data support an association between the development of <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> at the time of active EBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and ORTHOCLONE OKT3 administration in pediatric liver allograft recipients. (See: <a href="#AE_Infections">ADVERSE EVENTS, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a>, <a href="#AE_Neoplasia">Neoplasia</a>.)</p>
<p>Following the initiation of ORTHOCLONE OKT3 therapy, patients should be continuously monitored for evidence of <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> through physical examination and histological evaluation of any suspect lymphoid tissue. Close surveillance is advised, since early detection with subsequent reduction of total <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may result in regression of some of these <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. Since the potential for the development of <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> is related to the duration and extent (intensity) of total <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, physicians are advised: to adhere to the recommended dosage and duration of ORTHOCLONE OKT3 therapy; to limit the number of courses of ORTHOCLONE OKT3 and other anti- T lymphocyte antibody preparations administered within a short period of time; and, if appropriate, to reduce the dosage(s) of immunosuppressive drugs used concomitantly to the lowest level compatible with an effective therapeutic response. (See: <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>A recent study examined the incidence of non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (NHL) among 45,000 kidney transplant recipients and over 7,500 heart transplant recipients. This study suggested that all transplant patients, regardless of the immunosuppressive regimen employed, are at increased risk of NHL over the general population. The relative risk was highest among those receiving the most aggressive regimens.</p>
<p>The long-term risk of neoplastic events in patients being treated with ORTHOCLONE OKT3 has not been determined.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="PRECAUTIONS_General"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">When using combinations of immunosuppressive agents, the dose of each agent, including ORTHOCLONE OKT<span class="Sup">®</span>3, should be reduced to the lowest level compatible with an effective therapeutic response so as to reduce the potential for and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and malignant transformations.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Fever"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h3>
<p class="First">If the temperature of the patient exceeds 37.8°C (100°F), it should be lowered by antipyretics before administration of each dose of ORTHOCLONE OKT3. The possibility of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Cytokine"></a><a name="section-8.1.2"></a><p></p>
<h3>Severe Cytokine Release Syndrome Versus <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h3>
<p class="First"><span class="Bold">It may not be possible to distinguish between an acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, etc.) and the Cytokine Release Syndrome. Potentially serious signs and symptoms having an immediate onset (usually within 10 minutes) following administration of ORTHOCLONE OKT3 are probably due to acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> is suspected, discontinue the drug immediately; do not resume therapy or re-expose the patient to ORTHOCLONE OKT3</span>. Clinical manifestations beginning approximately 30 to 60 minutes (or later) following administration of ORTHOCLONE OKT3 are more likely cytokine-mediated. (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>, <a href="#WARNINGS_Anaphylactic"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_CNS"></a><a name="section-8.1.3"></a><p></p>
<h3>Central Nervous System Events</h3>
<p class="First">Since some <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (and other serious central nervous system events) following ORTHOCLONE OKT3 administration have been life-threatening, anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> precautions (e.g., an airway ready for use, if needed) should be taken. (See: <a href="#WARNINGS">WARNINGS</a> and ADVERSE EVENTS: Central Nervous System Events.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Infection"></a><a name="section-8.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>/Viral-Induced <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorders</span></h3>
<p class="First">If <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or a viral induced <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> occurs, culture or biopsy as soon as possible, promptly institute appropriate anti-infective therapy, and (if possible) reduce /discontinue immunosuppressive therapy. (See: <a href="#WARNINGS">WARNINGS</a>, <a href="#AE">ADVERSE EVENTS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Low"></a><a name="section-8.1.5"></a><p></p>
<h3>Low Protein-Binding Filter</h3>
<p class="First">Use a low protein-binding 0.2 or 0.22 micrometer (µm) filter to prepare the injections. (See: <a href="#ADMINISTRATION">ADMINISTRATION INSTRUCTIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Sensitization"></a><a name="section-8.1.6"></a><p></p>
<h3>Sensitization</h3>
<p class="First">ORTHOCLONE OKT3 is a mouse (immunoglobulin) protein that can induce human anti-mouse antibody production (i.e., sensitization) in some patients following exposure; a titer ≥1:1000 is a contraindication for use. (See: <a href="#WARNINGS">WARNINGS</a>, <a href="#AE">ADVERSE EVENTS</a>.)</p>
<p>In the initial clinical trials using low doses of prednisone and azathioprine during ORTHOCLONE OKT3 therapy for renal allograft rejection, antibodies to ORTHOCLONE OKT3 were observed with an incidence of 21% (n=43) for IgM, 86% (n=43) for IgG and 29% (n=35) for IgE. The mean time of appearance of IgG antibodies was 20 ± 2 days (mean ± SD). Early IgG antibodies appeared towards the end of the second week of treatment in 3% (n=86) of the patients.</p>
<p>Subsequent clinical experience has shown that the dose, duration, and type of immunosuppressive medications used in combination with ORTHOCLONE OKT3 may affect both the incidence and magnitude of the host antibody response. Furthermore, immunosuppressive agents used concomitantly with ORTHOCLONE OKT3 (i.e., steroids, azathioprine, prednisone, or cyclosporine) have altered the time course of anti-mouse antibody development and the specificity of the antibodies formed (i.e., idiotypic, isotypic, allotypic).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Thrombosis"></a><a name="section-8.1.7"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h3>
<p class="First">As with other immunosuppressive therapies, arterial, venous, and capillary thromboses of allografts and other vascular beds (e.g., heart, lungs, brain, bowel, etc.) have been reported in patients treated with ORTHOCLONE OKT3. In addition, microangiopathic changes (e.g., platelet microthrombi) in the renal allograft associated in some patients with <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">microangiopathic hemolytic anemia</span> have been reported. This was observed in 5 of 93 (5%) patients receiving doses above the recommended dose. The relationship to dose remains uncertain; however, the relative risk appears to be greater with doses above the recommended dose. Patients with a history of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or underlying vascular disease should be given ORTHOCLONE OKT3 only when the potential benefits clearly outweigh the increased risks of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="PRECAUTIONS_Information"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised:</p>
<ul class="Disc">
<li> of the signs and symptoms associated with the Cytokine Release Syndrome and the potentially serious nature of this syndrome (e.g., systemic, cardiovascular, central nervous system events).</li>
<li> to seek medical attention for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, rapid heart beat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, or any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> suggesting an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</li>
<li> that ORTHOCLONE OKT3 may impair mental alertness and coordination and may effect the ability to operate an automobile or machinery.</li>
<li> of other risks associated with the use of ORTHOCLONE OKT3. (See: <a href="#BOX">BOXED WARNING</a>; <a href="#WARNINGS">WARNINGS</a>; <a href="#PRECAUTIONS">PRECAUTIONS</a>; <a href="#AE">ADVERSE EVENTS</a>.)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="PRECAUTIONS_Laboratory"></a><a name="section-8.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The following tests should be monitored prior to and during ORTHOCLONE OKT<span class="Sup">®</span>3 therapy:</p>
<ul class="Disc">
<li> Renal: BUN, serum creatinine, etc.;</li>
<li> Hepatic: transaminases, alkaline phosphatase, bilirubin;</li>
<li> Hematopoietic: WBCs and differential, platelet count, etc.;</li>
<li> Chest X-ray within 24 hours before initiating ORTHOCLONE OKT3 treatment to rule out <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>.</li>
<li> Blood Tests: Periodic assessment of organ system functions (renal, hepatic, and hematopoietic) should be performed.</li>
</ul>
<p>During therapy with ORTHOCLONE OKT3: In adults, periodic monitoring to ensure plasma ORTHOCLONE OKT3 levels (≥800 ng/mL) or T cell clearance (CD3 positive T cells &lt;25 cells/mm<span class="Sup">3</span>) is recommended. In pediatric patients, <span class="Underline">both</span> plasma ORTHOCLONE OKT3 levels (≥800 ng/mL) and T cell clearance (CD3 positive T cells &lt;25 cells/mm<span class="Sup">3</span>) should be monitored daily. (See: <a href="#CP">CLINICAL PHARMACOLOGY</a>.)</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="PRECAUTIONS_Carcinogensis"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">Long-term studies have not been performed in laboratory animals to evaluate the carcinogenic potential of ORTHOCLONE OKT3; however, neoplasia has been reported in patients receiving this product. (See: <a href="#WARNINGS">WARNINGS</a> and <a href="#AE_Neoplasia"> ADVERSE EVENTS: Neoplasia</a>.)</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="PRECAUTIONS_Pregnancy"></a><a name="section-8.5"></a><p></p>
<h2>Pregnancy Category C</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.5.1"></a><p></p>
<p class="First">Animal reproductive studies have not been conducted with ORTHOCLONE OKT3. It is also not known whether ORTHOCLONE OKT3 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. However, ORTHOCLONE OKT3 is an IgG antibody and may cross the human placenta. The effect on the fetus of the release of cytokines and/or <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> after treatment with ORTHOCLONE OKT3 is not known. ORTHOCLONE OKT3 should be given to a pregnant woman only if clearly needed. If this drug is used during pregnancy, or the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. (See: <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>, <a href="#WARNINGS">WARNINGS</a>, and <a href="#AE">ADVERSE EVENTS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="PRECAUTIONS_Nursing"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether ORTHOCLONE OKT3 is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse events/oncogenesis shown for ORTHOCLONE OKT3 in human studies, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See: <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="PRECAUTIONS_Pediatric"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness have been established in infants (1 mo. up to 2 yr.); children (2 yr. up to 12 yr.); and adolescents (12 yr. up to 16 yr.). Use of ORTHOCLONE OKT3 in these age groups is supported by clinical studies that included adults and pediatric patients. In those studies, the safety and efficacy of ORTHOCLONE OKT3 in pediatric patients receiving renal or hepatic transplants was similar to that in the overall cohort. There were insufficient data to compare the safety and efficacy of ORTHOCLONE OKT3 in pediatric patients in a study of patients receiving cardiac transplants. Additional pharmacokinetic, pharmacodynamic, and clinical studies in infants, children, and adolescents have been reported in published literature.</p>
<p>Pediatric patients are known to have higher CD3 lymphocyte counts than adults; therefore, progressively higher doses of ORTHOCLONE OKT3 are often required to achieve therapeutic levels of lymphocyte clearance. (See: <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.1"></a><p></p>
<h3>Specific Safety Concerns in Pediatric Patients</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Deaths"></a><a name="section-8.7.1.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> Due to Cerebral Herniation</h4>
<p class="First">The postmarketing data base indicates that pediatric patients may be at increased risk of developing <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> with or without herniation compared to adults. In the period between 1986 and 1996, twenty-five cases (6 in pediatric patients) of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> were identified with subsequent cerebral herniation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in five cases (4 in pediatric patients). Herniation in the pediatric patients and one 19 year old subject occurred within a few hours to one day after the first dose (2.5 or 5 mg) of ORTHOCLONE OKT3 administered in the investigational setting for prophylaxis of renal allograft rejection. All pediatric patients and especially those receiving a renal allograft must be carefully evaluated for <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> before the initiation of ORTHOCLONE OKT3 therapy. (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>; <a href="#DA_General">DOSAGE AND ADMINISTRATION: General</a>.) Patients should be closely monitored for <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> during the first twenty four (24) hours following each of the first few doses of ORTHOCLONE OKT3 injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Other"></a><a name="section-8.7.1.2"></a><p></p>
<h4>Other Serious Central Nervous System Adverse Events</h4>
<p class="First">Other significant neurologic complications reported in pediatric transplant recipients receiving ORTHOCLONE OKT3 include <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, diffuse <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">cerebritis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, cortical dysfunction, and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>. Permanent neurologic impairments (e.g., <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>) have been reported rarely. Because <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> is a frequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> encountered in pediatric allograft recipients, and the <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> associated with transplantation increases the risk of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>, patients with <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningeal irritation</span> following treatment with ORTHOCLONE OKT3 therapy should be evaluated with lumbar puncture as early as possible to rule out an infectious etiology.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Viral"></a><a name="section-8.7.1.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span></h4>
<p class="First">The overall incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> appeared to be similar in pediatric patients compared to the overall population studied. In the pediatric population, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> often include pathogens uncommon in adults, such as <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV), adenovirus, enterovirus, parainfluenza virus, and respiratory syncytial virus (RSV). In addition, many viral diseases often manifest differently in pediatric patients than they do in adults. Because a large proportion of pediatric patients have not been infected by herpes viruses (e.g., EBV, HSV, CMV) prior to transplantation they may be more susceptible to acquiring primary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> from the grafted organ and/or blood products when immunosuppressed. Antiviral <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy may be particularly useful in these high risk pediatric patients. (See: <a href="#AE_Infections">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Neoplasia"></a><a name="section-8.7.1.4"></a><p></p>
<h4>Neoplasia</h4>
<p class="First">Patients with primary EBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be at higher risk for the development of EBV-associated <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. There are data to support an association between the development of <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> at the time of active EBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and ORTHOCLONE OKT<span class="Sup">®</span>3 administration in pediatric liver allograft recipients. Antiviral <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy may be particularly useful in these high risk pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_Gastrointestinal"></a><a name="section-8.7.1.5"></a><p></p>
<h4>Gastrointestinal <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Fluid Losses</span></h4>
<p class="First">Parenteral hydration may be required for gastrointestinal <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span> secondary to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> resulting from the "Cytokine Release Syndrome."</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PRECAUTIONS_PEDS_Thrombosis"></a><a name="section-8.7.1.6"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h4>
<p class="First">Pediatric patients may be at an increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. Pediatric patients weighing less than 15 kg are at high-risk for <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">hepatic artery thrombosis</span>. <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> has been reported in pediatric transplant recipients treated with ORTHOCLONE OKT3. A number of factors, including surgical technique, the presence of a hypercoaguable state, and the absence of prior dialysis experience may be relevant to the pathophysiology of the increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. (See: <a href="#BOX">BOXED WARNING</a>; <a href="#WARNINGS">WARNINGS</a>; <a href="#PRECAUTIONS">PRECAUTIONS</a>; <a href="#AE">ADVERSE EVENTS</a>; <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="PRECAUTIONS_Geriatric"></a><a name="section-8.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">There is no information on the use of OKT3 in geriatric patients. Caution should be used when prescribing immunosuppressive agents to elderly patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AE"></a><a name="section-9"></a><p></p>
<h1>ADVERSE EVENTS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AE_Cytokine"></a><a name="section-9.1"></a><p></p>
<h2>Cytokine Release Syndrome</h2>
<p class="First">In controlled clinical trials for treatment of acute renal allograft rejection, patients treated with ORTHOCLONE OKT3 plus concomitant low-dose immunosuppressive therapy (primarily azathioprine and corticosteroids) were observed to have an increased incidence of adverse experiences during the first two days of treatment, as compared with the group of patients receiving azathioprine and high-dose steroid therapy. During this period the majority of patients experienced <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (90%), of which 19% were 40.0°C (104°F) or above, and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (59%). In addition, other adverse experiences occurring in 8% or more of the patients during the first two days of ORTHOCLONE OKT3 therapy included: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (21%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (19%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (19%), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (14%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (14%), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (13%), <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> (13%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (11%), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (10%), rigor (8%), and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (8%). A similar spectrum of clinical manifestations has been observed in open clinical studies and in post-marketing experience involving patients treated with ORTHOCLONE OKT3 for rejection following renal, cardiac, and hepatic transplantation.</p>
<p>Additional serious and occasionally fatal cardiorespiratory manifestations have been reported following any of the first few doses. (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>; ADVERSE EVENTS: Cardiovascular, Respiratory.)</p>
<p>In the acute renal allograft rejection trials, potentially fatal <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> had been reported following the first two doses in less than 2% of the patients treated with ORTHOCLONE OKT3. <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span> was usually associated with <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>. However, post-marketing experience revealed that <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> has occurred in patients who appeared to be euvolemic, presumably as a consequence of cytokine-mediated increased vascular permeability ("leaky capillaries") and/or reduced myocardial contractility/compliance (i.e., <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>). (See: <a href="#WARNINGS_Cytokine">WARNINGS: Cytokine Release Syndrome</a>; <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AE_Infections"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">In the controlled randomized renal allograft rejection trial conducted before cyclosporine was marketed, the most common <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during the first 45 days of ORTHOCLONE OKT3 therapy were due to herpes simplex virus (27%) and cytomegalovirus (19%). Other severe and life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were <span class="Italics">Staphylococcus epidermidis</span> (5%), <span class="Italics">Pneumocystis carinii</span> (3%), <span class="Italics">Legionella </span>(2%), <span class="Italics">Cryptococcus</span> (2%), <span class="Italics">Serratia</span> (2%) and gram-negative bacteria (2%). The incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was similar in patients treated with ORTHOCLONE OKT3 and in patients treated with high-dose steroids.</p>
<p>In a clinical trial of acute hepatic allograft rejection, refractory to conventional treatment, the most common <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> reported in patients treated with ORTHOCLONE OKT3 during the first 45 days of the study were cytomegalovirus (16% of patients, of which 43% of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were severe), <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (15% of patients, of which 30% were severe), and herpes simplex virus (8% of patients, of which 10% were severe). Other severe and life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were gram-positive <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (9% of patients), gram-negative <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (8% of patients), <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (2% of patients), and <span class="Italics">Legionella</span> (1% of patients). In another trial studying the use of ORTHOCLONE OKT<span class="Sup">®</span>3 in patients with hepatic allografts, the incidence of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> was 34% and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with the herpes simplex virus was 31%.</p>
<p>In a clinical trial studying the use of ORTHOCLONE OKT3 in patients with acute cardiac rejection refractory to conventional treatment, the most common <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the ORTHOCLONE OKT3 group reported during the first 45 days of the study were herpes simplex virus (5% of patients, of which 20% were severe), <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (4% of patients, of which 75% were severe), and cytomegalovirus (3% of patients, of which 33% were severe). No other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported during this period.</p>
<p>In a retrospective analysis of pediatric patients treated for acute hepatic rejection, the most common <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> reported in patients treated with ORTHOCLONE OKT3 therapy were due to <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (47%), <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (21%), cytomegalovirus (19%), herpes simplex virus (15%), adenovirus (8%), and Epstein-Barr virus (8%). The overall rates of viral, fungal, and <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> were similar in patients treated with ORTHOCLONE OKT3 (n = 53) and in patients whose rejection was treated with steroids alone (n = 27). In another study of 149 pediatric liver allograft patients where 59 episodes of steroid-resistant rejection were treated with ORTHOCLONE OKT3, the incidence of invasive <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">cytomegalovirus infection</span> was higher in patients receiving ORTHOCLONE OKT3 than in those receiving steroids alone.</p>
<p>Clinically significant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, etc.) due to the following pathogens have been reported:</p>
<table width="100%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="80%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><span class="Italics">Bacterial:</span></td>
<td align="left">
<span class="Italics">    Clostridium</span> species (including <span class="Italics">perfringens</span>), <span class="Italics">Corynebacterium,</span> Enterococcus<span class="Italics">, Enterobacter aerogenes, Escherichia coli, Klebsiella</span> species, <span class="Italics">Lactobacillus, Legionella, Listeria monocytogenes, Mycobacteria </span>species, <span class="Italics">Nocardia asteroides, Proteus</span> species, <span class="Italics">Providencia</span> species, <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Serratia</span> species, <span class="Italics">Staphylococcu</span>s species, <span class="Italics">Streptococcus</span> species, <span class="Italics">Yersinia enterocolitica</span>, and other gram-negative bacteria.</td>
</tr>
<tr>
<td align="left"><span class="Italics">Fungal: <span class="Bold">*</span></span></td>
<td align="left">
<span class="Italics">  Aspergillus</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Cryptococcus, Dermatophytes</span>.</td>
</tr>
<tr>
<td align="left"><span class="Italics">Protozoa:</span></td>
<td align="left">
<span class="Italics">Pneumocystis carinii, Toxoplasma gondii</span>.</td>
</tr>
<tr class="Botrule Last">
<td align="left"><span class="Italics">Viral:</span></td>
<td align="left">cytomegalovirus<span class="Bold">*</span> (CMV), Epstein-Barr virus<span class="Bold Italics">*</span> (EBV), herpes simplex virus<span class="Bold">*</span> (HSV), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses<span class="Italics">, </span><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV), adenovirus, enterovirus, respiratory syncytial virus (RSV), parainfluenza virus.</td>
</tr>
</tbody>
</table>
<p>As a consequence of being a potent immunosuppressive, the incidence and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with designated(<span class="Bold">*</span>) pathogens, especially the herpes family of viruses, may be increased. (See: <a href="#WARNINGS_Infections">WARNINGS: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AE_Neoplasia"></a><a name="section-9.3"></a><p></p>
<h2>Neoplasia</h2>
<p class="First">In patients treated with ORTHOCLONE OKT3, post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> have ranged from <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> or benign polyclonal B cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasias</span> to malignant and often fatal monoclonal B cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>. In post-marketing experience, approximately one-third of the lymphoproliferations reported were benign and two-thirds were malignant. <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> types included: B cell, large cell, polyclonal, non-Hodgkin's, lymphocytic, T cell, Burkitt's. The majority were not histologically classified. <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Malignant lymphomas</span> appear to develop early after transplantation, the majority within the first four months post-treatment. Many of these have been rapidly progressive. Some were fulminant, involving the allografted organ and were widely disseminated at the time of diagnosis. Carcinomas of the skin included: basal cell, squamous cell, <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, melanoma, and <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span>. Other neoplasms infrequently reported include: <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, carcinoma of the breast, adenocarcinoma, <span class="product-label-link" type="condition" conceptid="4321680" conceptname="Cholangiocarcinoma">cholangiocarcinoma</span>, and recurrences of pre-existing <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> and renal cell carcinoma. (See: <a href="#WARNINGS_Neoplasia">WARNINGS: Neoplasia</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AE_Hypersensitivity"></a><a name="section-9.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Reported adverse reactions resulting from the formation of antibodies to ORTHOCLONE OKT3 have included antigen-antibody (immune complex) mediated syndromes and IgE-mediated reactions. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have ranged from a mild, self-limited <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> to severe, life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including: <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">swelling of lips</span>, eyelids, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngeal spasm</span> and airway obstruction with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>). (See: <a href="#WARNINGS_Anaphylactic">WARNINGS: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a>.)</p>
<p>Other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have included: ineffectiveness of treatment, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, allergic interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, immune complex deposition resulting in <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> (including temporal and retinal), and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AE_by_Body_System"></a><a name="section-9.5"></a><p></p>
<h2>Adverse Reactions by Body System</h2>
<p class="First">Adverse events reported in greater than or equal to 1% of clinical trial patients treated with ORTHOCLONE OKT3 (n=393) are shown in Table 1:</p>
<table width="80%">
<caption><span>Table 1: Adverse Events Reported in Clinical Trials (≥1% incidence, n=393)</span></caption>
<col align="left" valign="top" width="80%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left">Body System</th>
<th align="center">Incidence (%)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Diaphoresis</span></td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Vasodilation</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left"><span class="Bold">Body as a Whole, General Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td align="center">43</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td align="center">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, trunk</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">77</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span></td>
<td align="center">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td align="center">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">19</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td align="center">25</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, chest</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center">26</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span></td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="2"><span class="Bold">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">28</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">14</td>
</tr>
<tr>
<td align="left"><span class="Bold">Gastrointestinal System Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">37</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">32</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, abdominal</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, GI</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">25</td>
</tr>
<tr>
<td align="left"><span class="Bold">Hematopoietic Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Metabolic and Nutritional Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="center">12</td>
</tr>
<tr>
<td align="left"><span class="Bold">Musculoskeletal System Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">7</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disorders</span></span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Renal Dysfunction</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="73026" conceptname="Abnormal breath sounds">Abnormal Chest Sound</span></td>
<td align="center">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">16</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span></td>
<td align="center">7</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span></td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">Respiratory Congestion</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Appendages Disorders</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center">7</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">14</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Erythematous</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Special Senses</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span></td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="2"><span class="Bold">White Cell and Reticuloendothelial System Disorders</span></td></tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td align="center">7</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2>Selected Adverse Events Reported In Clinical Trials (&lt; 1% incidence, n=393)</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General: </span>Angina, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac Arrest</span>, Fluctuation in Blood Pressure, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>.</p>
<p><span class="Bold">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Hypotonia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span>.</p>
<p><span class="Bold">Hemapoietic Disorders: </span><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulation Disorder</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span>.</p>
<p><span class="Bold">Hepatobiliary:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> Increased, SGPT Increased.</p>
<p><span class="Bold">Psychiatric Disorders: </span><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood Changes</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">Paranoia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, Hearing Decrease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.7"></a><p></p>
<h2>Worldwide Postmarketing Experience - Body Systems/Events Listed Alphabetically</h2>
<p class="First"><span class="Bold">Body as a Whole, General Disorders: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (including spiking temperatures as high as 107°F), Flu-like Syndrome.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular Collapse</span>, <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">Hemodynamic Instability</span>, <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span>.</p>
<p><span class="Bold">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Aphasia</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">Asterixis</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">Cerebritis</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral Edema</span>, Cerebral Herniation, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular Accident</span>, CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, CNS Malignancy, Cranial Nerve VI <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">Palsy</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">Encephalitis</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">Hyperreflexia</span>, Involuntary Movements, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span>, Impaired Cognition, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Obnubilation</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">Paresis</span>/plegia including <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>/plegia, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span>, Transient Ischemic Attack, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>.</p>
<p>In a post-marketing survey involving 214 renal transplant patients, the incidence of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome was 6%. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (89%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (44%), <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">neck stiffness</span> (14%), and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> (10%) were the most commonly reported symptoms; a combination of these four symptoms occurred in 5% of patients.</p>
<p>Between 1987 and 1992, 75 post-marketing reports have described <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, averaging about 12 per year, and including 23 fatalities. More than two-thirds of these reports (53) were of domestic spontaneous origin, and their age and sex distributions were broad. Post-licensure reports generally provide insufficient data to allow accurate estimation of risk or of incidence.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> Bowel <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>.</p>
<p><span class="Bold">Hematopoietic Disorders:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, Arterial, Venous and Capillary <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> of allografts and other vascular beds e.g., heart, lung, brain and bowel etc., <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated Intravascular Coagulation</span>, Microangiopathic Changes (e.g., platelet microthrombi), <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">Microangiopathic Hemolytic Anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>.</p>
<p><span class="Bold">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> or Hepato/<span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, usually secondary to <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> or <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>.</p>
<p>Reactivation of <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span> including CMV, EBV, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B virus (HBV), and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C virus (HCV).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Stiffness</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Aches</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Azotemia</span>, Abnormal Urinary <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">Cytology</span> including <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">exfoliation</span> of damaged <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, collecting duct cells and cellular casts, Delayed Graft Function, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>/<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span>, usually transient and reversible and occasionally in association with Cytokine Release Syndrome.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory Arrest</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span>.</p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>, Nasal and Ear Stuffiness, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">Papilledema</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OD"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms of overdosage with ORTHOCLONE OKT<span class="Sup">®</span>3 may include <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, severe <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. A high incidence (5%) of <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">microangiopathic hemolytic anemia</span>/HUS syndrome in patients receiving 10 mg per day of ORTHOCLONE OKT3 was also reported. In the event of acute overdosage with ORTHOCLONE OKT3, the patient should be carefully observed and given symptomatic and supportive treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The recommended dose of ORTHOCLONE OKT3 for the treatment of acute renal, steroid-resistant cardiac, or steroid-resistant hepatic allograft rejection is 5 mg per day in a single (bolus) intravenous injection in less than one minute for 10 to 14 days. For acute renal rejection, treatment should begin upon diagnosis. For steroid-resistant cardiac or hepatic allograft rejection, treatment should begin when the treating physician deems a rejection has not been reversed by an adequate course of corticosteroid therapy. (See: <a href="#CP">CLINICAL PHARMACOLOGY</a>; <a href="#PRECAUTIONS_Sensitization">PRECAUTIONS: Sensitization</a>, <a href="#PRECAUTIONS_Laboratory">Laboratory Tests</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">The initial recommended dose is 2.5 mg per day in pediatric patients weighing less than or equal to 30 kg and 5 mg per day in pediatric patients weighing greater than 30 kg in a single (bolus) intravenous injection in less than one minute for 10 to 14 days. Daily increases in ORTHOCLONE OKT3 doses (i.e., 2.5 mg increments) may be required to achieve depletion of CD3 positive cells (&lt;25 cells/mm<span class="Sup">3</span>) and ensure therapeutic ORTHOCLONE OKT3 serum concentrations (&gt; 800 ng/mL). Pediatric patients may require augmentation of the ORTHOCLONE OKT3 dose. For acute renal rejection, treatment should begin upon diagnosis. For steroid-resistant cardiac or hepatic allograft rejection, treatment should begin when the treating physician deems a rejection has not been reversed by an adequate course of corticosteroid therapy. (See: <a href="#CP">CLINICAL PHARMACOLOGY</a>; <a href="#PRECAUTIONS_Laboratory">PRECAUTIONS: Laboratory Tests</a>; <a href="#PRECAUTIONS_Pediatric">Pediatric Use</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DA_General"></a><a name="section-11.3"></a><p></p>
<h2>General</h2>
<p class="First">For the first few doses, patients should be monitored in a facility equipped and staffed for cardiopulmonary resuscitation (CPR). Patients receiving subsequent doses of ORTHOCLONE OKT3, should also be monitored in a facility equipped and staffed for CPR. Vital signs should be monitored frequently. Patients receiving ORTHOCLONE OKT3 should also be carefully monitored for signs and symptoms of Cytokine Release Syndrome, particularly after the first few doses but also after a treatment hiatus with resumption of therapy. The patient's temperature should be lowered to &lt;37.8°C (100°F) before the administration of any dose of ORTHOCLONE OKT3.</p>
<p>Prior to administration of ORTHOCLONE OKT3, the patient's volume status should be assessed carefully. It is imperative, especially prior to the first few doses, that there be no clinical evidence of volume overload, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>, or uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients should have a clear chest X-ray and should not weigh more than 3% above their minimum weight during the week prior to injection.</p>
<p>To decrease the incidence and severity of Cytokine Release Syndrome, associated with the first dose of ORTHOCLONE OKT3, it is strongly recommended that methylprednisolone sodium succinate 8.0 mg/kg be administered intravenously 1 to 4 hours prior to the initial dose of ORTHOCLONE OKT3. Acetaminophen and antihistamines given concomitantly with ORTHOCLONE OKT3 may also help to reduce some early reactions. (See:<a href="#WARNINGS"> WARNINGS</a> and <a href="#AE_Cytokine">ADVERSE EVENTS: Cytokine Release Syndrome</a>.)</p>
<p>When using concomitant immunosuppressive drugs, the dose of each should be reduced to the lowest level compatible with an effective therapeutic response in order to reduce the potential for malignancy and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Maintenance <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> should be resumed approximately three days prior to the cessation of ORTHOCLONE OKT<span class="Sup">®</span>3 therapy. (See: <a href="#WARNINGS">WARNINGS</a> and <a href="#AE_Infections">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a>, <a href="#AE_Neoplasia">Neoplasia</a>.)</p>
<p>Reduced T cell clearance or low plasma ORTHOCLONE OKT3 levels provide a basis for adjusting ORTHOCLONE OKT3 dosage or for discontinuing therapy. (See: <a href="#WARNINGS_Anaphylactic">WARNINGS: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a>; <a href="#PRECAUTIONS_Laboratory">PRECAUTIONS: Laboratory Tests</a>; <a href="#AE_Hypersensitivity">ADVERSE EVENTS: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ADMINISTRATION"></a><a name="section-11.4"></a><p></p>
<h2>Administration Instructions</h2>
<ol class="Arabic">
<li>Before administration, ORTHOCLONE OKT3 should be inspected for particulate matter and discoloration. Because ORTHOCLONE OKT3 is a protein solution, it may develop fine translucent particles (shown not to affect potency).</li>
<li>No bacteriostatic agent is present in this product. Adherence to aseptic technique is advised. Once the ampule is opened, use immediately and discard the unused portion.</li>
<li>Prepare ORTHOCLONE OKT3 for injection by drawing solution into a syringe through a low protein-binding 0.2 or 0.22 micrometer (µm) filter. Detach filter and attach a new needle for a single intravenous (bolus) injection.</li>
<li>Because no data is available on compatibility of ORTHOCLONE OKT3 with other intravenous substances or additives, other medications/substances should not be added or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with saline before and after injection of ORTHOCLONE OKT3.</li>
<li>Administer ORTHOCLONE OKT3 as a single intravenous (bolus) injection in less than one minute. Do <span class="Bold">not</span> administer by intravenous infusion or in conjunction with other drug solutions.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ORTHOCLONE OKT3 is supplied as a sterile solution in packages of 5 ampules (NDC 59676-101-01). Each 5 mL ampule contains 5 mg of muromonab-CD3.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store in a refrigerator at 2° to 8°C (36° to 46°F).</p>
<p>DO NOT FREEZE OR SHAKE.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Adair JC, Woodley SL, O'Connell JB, <span class="Italics">et al</span>. <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> following Cardiac Transplantation: Clinical Characteristics and Relationship to Immunosuppressive Regimen. Neurology <span class="Underline">41</span>:249–252, 1991.</li>
<li>Chatenoud L, Legendre C, Ferran C, <span class="Italics">et al</span>. Corticosteroid Inhibition of the OKT3 - Induced Cytokine-Related Syndrome - Dosage and Kinetics Prerequisites. Transplantation <span class="Underline">51</span>:334–338, 1991.</li>
<li>Cockfield SM, Preiksaitis J, Harvey E, Jones C, Herbert D, Keown P, and Halloran PF, <span class="Italics">et al</span>. Is Sequential Use of ALG and OKT3 in Renal Transplants Associated with an Increased Incidence of Fulminant <span class="product-label-link" type="condition" conceptid="42872948" conceptname="Post transplant lymphoproliferative disorder">Post Transplant Lymphoproliferative Disorders</span>? Transplant. Proc. <span class="Underline">23</span>:1106–1107, 1991.</li>
<li>Ettenger RB, Marik J, Rosenthal JT, <span class="Italics">et al</span>. OKT3 for Rejection Reversal in Pediatric Renal Transplantation. Clin. Transplantation <span class="Underline">2</span>:180–184, 1988.</li>
<li>Gaston RS, Deierhoi MH, Patterson T, <span class="Italics">et al</span>. OKT3 First-Dose Reaction: Association with T Cell Subsets and Cytokine Release. Kid. International <span class="Underline">39</span>:141–148, 1991.</li>
<li>Goldman M, Abramowicz D, DePauw L, <span class="Italics">et al</span>. OKT3-Induced Cytokine Released Attenuation by High-Dose Methylprednisolone. Lancet <span class="Underline">2</span>:802–803, 1989.</li>
<li>Ortho Multicenter Transplant Study Group. A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants. N. Engl. J. Med. <span class="Underline">313</span>:337–342, 1985.</li>
<li>Penn I. The Changing Patterns of Posttransplant Malignancies. Transplant. Proc. <span class="Underline">23</span>:1101–1103, 1991.</li>
<li>Rubin RH and Tolkoff-Rubin NE. The Impact of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> on the Outcome of Transplantation. Transplant. Proc. <span class="Underline">23</span>:2068–2074, 1991.</li>
<li>Schroeder TJ, Ryckman FC, Hurtubise PE, <span class="Italics">et al</span>. Immunological Monitoring During and Following OKT3 Therapy in Children. Clin. Transplantation <span class="Underline">5</span>:191–196, 1991.</li>
<li>Goldstein G, Fuccello AJ, Norman DJ, <span class="Italics">et al</span>. OKT3 Monoclonal Antibody Plasma Levels During Therapy and the Subsequent Development of Host Antibodies to OKT3. Transplantation <span class="Underline">42</span>:507–511, 1986.</li>
<li>Schroeder TJ, Michael AT, First MR, <span class="Italics">et al</span>. Variations in Serum OKT3 Concentration Based Upon Age, Sex, Transplanted Organ, Treatment Regimen, and Anti-OKT3 Status. Therapeutic Drug Monitoring <span class="Underline">16</span>:361–367, 1994.</li>
<li>First MR, Schroeder TJ, Hurtubise PE, <span class="Italics">et al</span>. Immune Monitoring During Retreatment with OKT3. Transplan. Proc. <span class="Underline">21</span>:1753–1754, 1989.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Centocor Ortho Biotech Products, L.P.</p>
<p>Raritan, New Jersey 08869</p>
<p>U.S.A.</p>
<p>©COBPLP 2001<br> Printed in U.S.A.<br> Revised:  May 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Carton</h1>
<p class="First">5 Ampules<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">ORTHOCLONE OKT</span><span class="Sup">®</span><span class="Bold">3<br><span class="Sup">Pr</span>Muromonab-CD3</span><br> Injection<br><span class="Bold">5 mg/5 mL<br></span>(1 mg/mL)<br> For Intravenous Use Only</p>
<p>Manufactured by:<br> Centocor Ortho Biotech Products, L.P.<br> Raritan, NJ 08869<br> U.S. License No. 1824</p>
<p><span class="Bold">Centocor Ortho Biotech Products, L.P.</span></p>
<p><span class="Bold">NDC</span> 59676-101-01
						</p>
<p>Sterile Solution —<br> No Preservative
						</p>
<p>ATTENTION: Filter<br> Precaution—See Insert.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2a1f1c18-fa95-45e6-bd00-ac53c73f4747&amp;name=orthoclone-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OKT3 		
					</strong><br><span class="contentTableReg">muromonab-cd3 injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59676-101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>muromonab-CD3</strong> (muromonab-CD3) </td>
<td class="formItem">muromonab-CD3</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem">2.25 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">9 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">43 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">1 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59676-101-01</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59676-101-00</td>
<td class="formItem">5 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103463</td>
<td class="formItem">07/19/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Centocor Ortho Biotech Products, L.P.
							(804684207)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Centocor Ortho Biotech Products, L.P.</td>
<td class="formItem"></td>
<td class="formItem">804684207</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ortho-McNeil-Janssen Pharmaceutical, Inc.</td>
<td class="formItem"></td>
<td class="formItem">010779978</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0993081a-81b0-43c7-a8dc-a21b2f7dcaea</div>
<div>Set id: 2a1f1c18-fa95-45e6-bd00-ac53c73f4747</div>
<div>Version: 3</div>
<div>Effective Time: 20110523</div>
</div>
</div> <div class="DistributorName">Centocor Ortho Biotech Products, L.P.</div></p>
</body></html>
